Brief: Transgene Expands Phase II Clinical Trial Of Therapeutic Vaccine TG4001

Transgene SA

10/03/2021 17:20

March 10 (Reuters) - TRANSGENE SA  TRNG.PA :
    * TRANSGENE EXPANDS PHASE II CLINICAL TRIAL OF THERAPEUTIC
VACCINE
TG4001 IN COMBINATION WITH AVELUMAB VERSUS AVELUMAB MONOTHERAPY
IN PATIENTS WITH HPV16-POSITIVE ANOGENITAL CANCERS
    * ENROLLMENT OF FIRST PATIENT IS EXPECTED IN Q2 2021
    * CONTINUED CLINICAL COLLABORATION WITH MERCK KGAA,
DARMSTADT,
GERMANY, AND PFIZER TO CONDUCT EXPANDED PHASE II STUDY
    * TRIAL WILL FOCUS ON PATIENTS WITHOUT LIVER METASTASES,
BASED ON
ENCOURAGING DATA IN PHASE IB/II STUDY
    * TRIAL TARGETS INDICATIONS WHERE CLINICAL OUTCOMES CAN BE
IMPROVED VERSUS STANDARD THERAPEUTIC OPTIONS AND IMMUNE
CHECKPOINT INHIBITORS ("ICIS")
    * EXPECTS TO COMMUNICATE INTERIM ANALYSIS DATA AROUND END OF
2022
    * THIS TIMELINE IS BASED ON PATIENT ENROLLMENT STARTING IN
Q2 2021
AND THERE BEING NO MAJOR IMPACT ON RECRUITMENT FROM COVID-19
PANDEMIC

Source text for Eikon:  ID:nBw84WRhla 
Further company coverage:  TRNG.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))